The use of stable isotope labeling has revolutionized NMR studies of nucleic acids, and there is a need for methods of incorporation of specific isotope labels to facilitate specific NMR experiments and applications. Enzymatic synthesis offers an efficient and flexible means to synthesize nucleoside triphosphates from a variety of commercially available specifically labeled precursors, permitting isotope labeling of RNAs prepared by in vitro transcription. Here, we recapitulate de novo pyrimidine biosynthesis in vitro, using recombinantly expressed enzymes to perform efficient single-pot syntheses of UTP and CTP that bear a variety of stable isotope labeling patterns. Filtered NMR experiments on 13 C, 15 N, 2 Hlabeled HIV-2 TAR RNA demonstrate the utility and value of this approach. This flexible enzymatic synthesis will make implementing detailed and informative RNA stable isotope labeling schemes substantially more cost-effective and efficient, providing advanced tools for the study of structure and dynamics of RNA molecules.
Introduction
Enzymatic synthesis has emerged as an important tool in the production of biochemicals. Enzyme catalyzed reactions are often more specific, efficient, cost-effective, and afford reduced environmental impact over traditional chemical methods. [1] [2] [3] [4] Because of these advantages, many straightforward enzymatic schemes have been adopted in industrial biochemical production. 5 Recent advances in metabolic engineering have greatly broadened the targets and applications for enzymatic synthesis, which now contributes significantly to the biofuel industry 6, 7 and natural products synthesis. 8 In particular, the development of enzymatic tools to synthesize nucleotides has had a tremendous impact on the study of RNA, DNA, and other nucleic acids by nuclear magnetic resonance (NMR) methods. 9 Multinuclear NMR experiments require the incorporation of one or more stable isotope labels, and therefore synthetic methods to incorporate isotope labels into nucleic acid building blocks have driven a significant advance in structural studies, including allowing the study of larger molecules. 10 In particular, there is a need for pyrimidine nucleotides that are selectively isotope labeled to complement the specifically labeled purine nucleotides that are commercially available and/or obtained efficiently using published methods.
11
The primary method to obtain stable isotope labeled nucleotides is the harvest of uniformly 13 C, 15 N-labeled nucleotides from bacteria grown on labeled media containing 15 NH 4 Cl and 13 C-glucose or 13 C-methanol. [12] [13] [14] This biomass method is suitable for economic production of uniformly labeled nucleotides in large quantity, but does not allow for efficient sitespecific incorporation of stable isotopes at designated locations without specialized labeled medium, metabolically modified bacteria, or both. Selective incorporation of 15 N, 13 C into nucleic acids is extremely useful to highlight specific resonances, to facilitate selective magnetization transfer pathways, and to simplify spectra. Using 13 C, 2 H-glucose and unlabeled bases, enzymatic methods for the selective deuteration of the ribose moiety of nucleotides have allowed the study of RNA of increasing size by effectively editing spectra to allow for the assignment of intermolecular and sugar-sugar NOEs.
15 Using this method, the H 1′ and H 2′ protons can be selectively observed, providing important structural information, and a variety of † Specifically deuterated CDP has been chemically synthesized from tert-butyldimethylsilyl cytidine derivatives with ∼17% overall yield for both 2 H 2′ and 2 H 3′ labels. 22 Here we report a total enzymatic synthesis of UTP and CTP through the expansion of our current enzymatic methods to the de novo pyrimidine biosynthetic pathway. The result is an efficient flexible method to incorporate 15 N, 13 C, and 2 H into both the base and ribose moieties of pyrimidine nucleotides.
Results and Discussion
Design of the Enzymatic Synthesis. In contrast to de novo purine synthesis, where the base is constructed step by step onto the ribose moiety, in de novo pyrimidine synthesis, the preformed nucleobase is enzymatically coupled to the ribose moiety, as shown in Scheme 1A. While the reconstitution of entire E. coli pathways in vitro has proven successful in many cases, 16, 23 several key substitutions proved necessary for efficient in vitro orotate synthesis using the de novo pyrimidine pathway. The carbamoyl-phosphate synthase-like carbamate kinase enzyme from thermophile Pyrococcus furiosus (cpkA) 24, 25 was substituted for E. coli carbamoyl phosphate synthase (carA/B) due to three advantages. First, cpkA utilizes NH 4 + as the nitrogen source, in contrast to the strict requirement for glutamine by carA/B, making the reaction more cost-effective. Second, the single subunit Pyrococcus enzyme cpkA is extremely stable and is easy to prepare. In contrast, E. coli carbamoyl phosphate carA/B proved unstable and required a challenging preparation of both subunits for optimal activity. Third, Pyrococcus cpkA worked under the conditions desired for pyrimidine nucleotide synthesis, eliminating the effects of the regulatory feedback of E.coli carA/B by UMP, UDP, and UTP in the one pot synthesis. 26 Although the E. coli enzymes for the de novo pyrimidine pathway downstream from E. coli carA/B functioned well, the requirement for ubiquinone as a hydrogen acceptor by E. coli dihydro-orotate dehydrogenase (pyrD) in the fourth step of de novo pyrimidine synthesis was very inconvenient. The possibility of ubiquinone recycling was daunting because the multisubunit membrane associated enzymes such as succinate dehydrogenase or NADH dehydrogenase would be required. However, dihydro-orotate dehydrogenase A (pydA) from Lactoccocus lactis (a class 1A member of the dihydro-orotate dehydrogenase family) uses fumarate as its hydrogen acceptor, and this enzyme-cofactor pair proved to be a suitable replacement. 27 Regeneration of ATP and NADP + , as shown in Scheme 1B, provides a driving force for the overall pyrimidine synthesis reaction. 28, 29 Several equivalents of creatine phosphate drive the immediate recharging of NMPs and NDPs to NTP by nucleotide kinases through mass action. Similarly, R-ketoglutarate and NH 4 + fuel the conversion of NADPH to NADP + providing the proper substrate for the NADP + dependent reactions to move forward. In addition dATP was substituted for ATP in all cases to prevent dilution of the NTP pool with unlabeled ATP. Although de novo pyrimidine enzymes cpkA and pyrG accept dATP with slightly reduced activity, the deoxynucleotide byproducts can be easily separated from the product NTPs during the affinity purification step.
With all of the proper components in place, the engineered de novo pyrimidine pathway was combined with pentose phosphate enzymes and cofactor regeneration of ATP and NADP + to synthesize UTP from HCO 3 -, NH 4 + , aspartate, and glucose in one pot. CTP was synthesized from UTP and NH 4 + in a separate reaction due to inhibition from components present in the first reaction.
30 Figure 1A ,B shows the overall reaction for synthesis of UTP and CTP. A relatively small number of components are necessary to build the pyrimidine ring. The metabolic origin of each atom is shown in Figure 1C ,D. The major contributor is aspartate, and due to the wide availability of specifically labeled forms of aspartate, many specific pyrimidine base labeled patterns can be synthesized including a combination of 13 C, 15 N, and 2 H. The exchange of C 6 proton with solvent during the decarboxylation of OMP is convenient for specific deuteration schemes. Deuteration at the C 5 position is often desired since the H 5 and H 1 chemical shifts are very similar, and C 5 deuteration has been accomplished previously through a separate chemical synthesis of 2 H 5 -uracil. 31 Using the de noVo enzymatic synthesis scheme, selective deuteration on both the base and ribose with simultaneous 15 N labeling was successful in a single pot reaction. There is one limitation placed on possible labeling patterns using this scheme due to the production of CO 2 by decarboxylation of OMP to UMP and 6-phosphogluconate to ribulose-5-phosphate during PRPP generation. These steps couple the carbon source for the C 2 of the pyrimidine ring to C 1 of aspartate and C 1 of glucose. Degassing and inert atmosphere are sufficient to prevent isotope dilution from air and solvent at the C 2 position (see Supplementary  Figure 8 ). If C 2 labeling is desired without ribose labeling, PRPP can be generated enzymatically from unlabeled ribose. 30 In addition, 13 C 1 -aspartate is readily available and can be included to label C 2 without C 4 , C 5 , C 6 labeling.
Implementation of the Enzymatic Synthesis. There are 18 enzymes required to implement the de novo enzymatic synthesis of UTP and CTP. The majority of the pentose phosphate pathway and cofactor recycling enzymes are commercially available or have been cloned previously. 16 The pyrimidine specific enzymes were cloned from E. coli given our previous success with other E. coli pathways. In addition, carbamoylphosphate synthase like carbamate kinase from Pyrococcus furiosus was cloned and substituted in the first step of the de novo pyrimidine pathway. Similarly, dihydro-orotate dehydrogenase was cloned from Lactococcus lactis and used in place of the E. coli enzyme in the fourth step of de novo pyrimidine synthesis. Due to the lack of suitable activity assays, it was not possible to determine the specific activities for steps 2-4 of de novo pyrimidine synthesis. Instead, an assumed specific activity of 0.5 U/mg was used for aspartate carbamoyl transferase, dihydro-orotase, and dihydro-orotate dehydrogenase. The amounts for the unassayed enzymes were empirically optimized during pilot scale reactions. For best results, it is advisible to use fresh preparations all of the enzymes to prepare nucleotides on a scale sufficient for transcription reactions. To illustrate the flexibility and utility of the enzymatic synthesis, five different labeled nucleotides were synthesized, as shown in Figure 2 . 
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(A) ConVersion of glucose to phosphoribosyl-pyrophosphate (PRPP).
Glucose and dATP are converted to glucose-6-phosphate (G6P) by the action of hexokinase (hxkA) with the production of dATP. G6P is interconverted to fructose-6-phosphate (F6P) by the action of phosphoglucose isomerase (pgi). G6P and NADP
+ are converted to 6-phosphogluconic acid (6PG) by the action of G6P-dehydrogenase (zwf) with the production of NADPH. 6PG and NADP + are converted to ribulose-5-phosphate (Ru5P) by the action of 6PG-dehydrogenase (gndA) with the production of NADPH. Ru5P is interconverted to ribose-5-phosphate (R5P) by the action of phosphoribose isomerase (rpiA). R5P and dATP are converted to PRPP by the action of PRPP synthase (prsA) with the production of dAMP. ConVersion of HCO 3 -and NH 4 + to UTP and CTP. HCO 3 -, NH 4 + , and dATP are converted to carbamoyl phosphate by the action of carbamate kinase-like carbamoyl phosphate synthase (cpkA) with the production of dADP. Carbamoyl phosphate and aspartate are converted to carbamoyl aspartate by the action of aspartate carbamoyl transferase (pyrB/I). Carbamoyl aspartate is converted to dihydro-orotate by the action of dihydro-orotase (pyrC). Dihydro-orotate and fumarate are converted to orotate by the action of dihydro-orotate dehydrogenase (pydA) with the production of succinate. Orotate and PRPP are converted to orotate monophosphate (OMP) by the action of orotate phosphoribosyl transferase (pyrE). OMP is converted to uridine monophosphate (UMP) by the action of orotate decarboxylase (pyrF) with the production of CO 2 . UMP is charged up to uridine triphosphate (UTP) as shown in ( 
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C 6,1′ -UTP. A 0.3 mmol scale synthesis was performed using 13 C 2 -glucose and 13 C 2 -aspartate. The labeled glucose and aspartate were combined with stoichiometric substrates (KHCO 3 , sodium fumarate, NH 4 Cl), fuel reagents (Rketoglutarate, creatine phosphate), catalytic cofactors (dATP, NADP + ) and the 15 enzymes listed in column 3 of Table 1 in a 30 mL buffered reaction. UTP formation was monitored by HPLC over the course of 3 days when the reaction ceased to progress. The time course of this synthesis is shown in Supporting Information Figure S6C . Affinity purification afforded a 25% yield based on input glucose. Figure S6D . Affinity purification afforded a 45% yield based on input glucose. Since equimolar amounts of aspartate and glucose are included in the reaction, the yield is also 45% based on input aspartate.
Synthesis of U-
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C-UTP. A 0.75 mmol scale synthesis was performed using U-C-glucose, U-13 C-aspartate, and NaH 13 CO 3 . The labeled substrates were combined with stoichiometric substrates (sodium fumarate, ammonium chloride), fuel reagents (R-ketoglutarate, creatine phosphate), catalytic cofactors (dATP, NADP + ), and the 15 enzymes listed in column 5 of Table 1 in a 75 mL buffered reaction. UTP formation was monitored by HPLC over the course of 2 days when the reaction ceased to progress. The time course of this synthesis is shown in Figure  3 . Affinity purification afforded a 40% yield based on input glucose.
Incorporation of Labeled Nucleotides into RNA. To demonstrate the utility of the labeled nucleotides, HIV-2 TAR RNA was transcribed in vitro using U- Figures S9 and S10 , respectively. The proton spectra are of particular interest since vital secondary and tertiary structural information can be gained through understanding the network of hydrogen bonding, base stacking and conformational features of base and ribose moieties. However, the informative areas of RNA proton spectra are naturally crowded, and it is extremely difficult to discern specific correlations.
Employing our specific labeling synthesis scheme, we set out to observe a particular interaction between the H 1′ and H 2′ protons of pyrimidine nucleotides with protons bonded to 13 C atoms on purines in HIV-2 TAR. The experiment focuses on the internucleotide distance constraints between the H 1′ and H 2′ protons of pyrimidine nucleotides and the 13 C bound protons of purine nucleotides. The 13 C, 15 N filtered-edited NOESY experiment, shown in Figure 4B , revealed the two expected NOE correlations in HIV-2 TAR where the protons are ∼2 Å apart: H 2′ of C4 to 13 C-H 8 of A5 and H 2′ of U26 to 13 C-H 8 of G27. Relative to the 13 C-edited NOESY spectrum, these two correlations represent a small fraction of the total number of NOE correlations typically observed. The application of filteredfiltered and edited-edited experiments using this labeling scheme would reveal proton-proton distance constraints within the populations of pyrimidines and purines, respectively.
Accessible site-specific labeling of pyrimidine bases will also advance the collection and quantitative analysis of dynamics measurements on the ps-ns and µs-ms time scales. To date, 13 C relaxation studies have been conducted on uniformly labeled samples and the associated data are complicated by magnetic interactions between adjacent 13 C atoms. Through the use of the one-pot synthesis scheme we present here, a variety of pyrimidine nucleotides that have 13 C at isolated positions in the base can be rapidly generated. In addition to extending the size of RNA molecules that can be studied, this labeling strategy will also enable the use of sensitive relaxation dispersion experiments to measure dynamics on the µs-ms time scale, instead of depending on the power dependence methodologies. 9 The relative ease and efficiency with which these nucleotides are synthesized should facilitate informative structural and dynamic studies of RNA molecules and complexes of increasing size.
Conclusions
Utilizing enzymes from several different species, we have designed an efficient and flexible method for site-specific labeling of pyrimidine nucleotides in the base and ribose moiety from readily available precursors. This method has allowed the synthesis of new labels with up to 45% yield based on input glucose and aspartate. We have shown that when used in welldesigned combinations, these labeled nucleotides enable extremely specific secondary structural features in RNA to be detected by NMR. In the future, we hope to expand our enzymatic synthesis to deoxyribonucleotides to create an equally valuable set of isotope editing tools for probing the secondary structures of DNA molecules. C-GTP were prepared as previously described.
Experimental Methods
Materials
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Enzyme Cloning. The genes for pyrI, pyrB, pyrC, pyrE, pyrF, pyrG, pyrH, and cmk were cloned from E. coli K12 MRE600 genome. The genes for cpkA from Pyrococcus furiosus and pydA from Lactococcus lactis were cloned from genomic DNA purchased from the ATCC (#19435 and #43587, respectively). All genes were cloned using standard procedures based on the reported sequence in Genbank. Gene specific primers with compatible sites for either BamHI, EcoRI or XhoI restriction endonucleases were used to insert all genes into ampicillin resistant plasmid pET22-HT (derived from pET22b, Novagen) encoding an N-terminal hexahistidine tag. In addition, pyrB was inserted into the kanamycin resistant plasmid pET28b (Novagen), also encoding an N-terminal hexahistidine tag. E. coli strain DH5R was used for cloning and plasmid maintenance. All constructs were verified by DNA sequencing.
Enzyme Purification. All plasmids were transformed into E. coli BL21 (DE3) cells for protein overexpression. Additionally, cpkA was transformed into the E. coli Rosetta (DE3) strain that enhanced expression. For pyrI/B coexpression, the cells were transformed with both pyrI-pET22HT and pyrB-pET28b, and grown with 200 µg/mL amplicillin and 100 µg/mL kanamycin. Briefly, overnight 5 mL cultures in LB with 200 µg/mL ampicillin were diluted 100 fold and grown at 37°C with shaking at 260 rpm until the OD 600 was ∼0.5. Protein expression was induced by addition of 1 mM IPTG, followed by growth for an additional 4-5 h. Cells were harvested by centrifugation at 10 000 ×g for 30 min. All steps after cell growth were carried out at 4°C. The cell pellets from 2 L of growth were gently resuspended in 200 mL 50 mM K-Hepes (pH 7.6), 1 M NaCl, 20 mM imidazole with 10% glycerol. Cell lysis was accomplished by sonication with 20 cycles of a 30 s pulse and 2 min rest at 70% power. The lysates were centrifuged at 31 000 ×g, and the supernatants were loaded directly to a Ni-NTA (Qiagen) column equilibrated with lysis buffer minus glycerol. The column was washed with 6 volumes of the same buffer and protein was eluted with 250 mM imidazole. The purified protein was dialyzed against 25 mM K-Hepes (pH 7.6), 50 mM NaCl, 5 mM -mercaptoethanol ( ME) with 50% glycerol. Dialysis for pyrG additionally contained 4 mM glutamine and 20 mM ME. Dialyzed enzymes were stored at -20°C and were active for at least 6 months with the exception of pyrG and pydA which began to lose activity after ∼2 weeks. Yields ranged from ∼30-100 mg of purified protein per liter of culture depending on the enzyme, but different preparations of each enzyme were generally consistent. Supporting Information Table S1 lists typical yields and specific activities for each de novo pyrimidine enzyme.
Enzymatic Assays. Enzymatic activity is reported in units (U), where 1 U is the amount of enzyme required to convert 1 µmol of substrate to product per minute. Specific activity is reported as U per mg of enzyme. Enzymatic activities were determined for all enzymes except pyrI/B, pyrC, and pydA by coupling the reaction to the consumption of ATP monitored by the change in A 340 due to the action of pyruvate kinase and lactate dehydrogenase ADP and NADH. 32 For the other enzymes, the estimated specific activity was assumed to be 0.5 U/mg. C-L-aspartic acid, 412 mg (7.5 each), 40 mM Tris HCl (pH 8.1), 0.1 mM spermidine, 10 mM DTT, 24 mM MgCl 2 , 0.001% Triton X-100, 80 mg/mL poly(ethylene glycol) (8000 MW), 300 nm each DNA strand (Invitrogen), and 1 mg/mL T7 RNA polymerase, incubated at 37°C for 5 h. The RNA was purified on denaturing 20% polyacrylamide gels, electro-eluted and desalted, lyophilized and diluted in 10 mM Na 2 HPO 4 /NaH 2 PO 4 (pH 6.5), 150 mM NaCl, 10% D 2 O for recording NMR spectra.
NMR Experiments. The spectral benefits of site-specifically labeling base residues with 13 C and 15 N isotopes were assessed with two-dimensional correlation spectroscopy. All spectra were collected at 25°C on a 900 MHz Bruker Avance spectrometer equipped with a triple resonance 5 mm TXI-HCN probe with triple-axis gradients. A 13 C, 15 N-filtered-edited NOESY spectrum of type "F1fF2e" was optimized for aromatic C-H correlations, acquired using a 250 ms mixing time according to published pulse programs, 33, 34 and compared to the analogous 13 C-F2-edited NOESY spectrum. C-HSQC spectra employed echo/antiecho gradient selection to remove the water signal. All spectra were referenced to 2,2-dimethyl-2-silapentane-5-sulfonate, processed with NMRPipe and viewed in NMRDraw.
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